- Home
- AUST vs ALXO Comparison
AUST vs ALXO Comparison
Compare AUST & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- ALXO
- Stock Information
- Founded
- AUST 2020
- ALXO 2015
- Country
- AUST Canada
- ALXO United States
- Employees
- AUST N/A
- ALXO N/A
- Industry
- AUST
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- ALXO Health Care
- Exchange
- AUST Nasdaq
- ALXO Nasdaq
- Market Cap
- AUST 21.2M
- ALXO 24.0M
- IPO Year
- AUST 2022
- ALXO 2020
- Fundamental
- Price
- AUST $1.33
- ALXO $0.43
- Analyst Decision
- AUST
- ALXO Strong Buy
- Analyst Count
- AUST 0
- ALXO 6
- Target Price
- AUST N/A
- ALXO $3.30
- AVG Volume (30 Days)
- AUST 74.6K
- ALXO 365.9K
- Earning Date
- AUST 08-06-2025
- ALXO 08-07-2025
- Dividend Yield
- AUST N/A
- ALXO N/A
- EPS Growth
- AUST N/A
- ALXO N/A
- EPS
- AUST N/A
- ALXO N/A
- Revenue
- AUST N/A
- ALXO N/A
- Revenue This Year
- AUST N/A
- ALXO N/A
- Revenue Next Year
- AUST N/A
- ALXO N/A
- P/E Ratio
- AUST N/A
- ALXO N/A
- Revenue Growth
- AUST N/A
- ALXO N/A
- 52 Week Low
- AUST $0.80
- ALXO $0.41
- 52 Week High
- AUST $3.19
- ALXO $8.78
- Technical
- Relative Strength Index (RSI)
- AUST 40.17
- ALXO 40.22
- Support Level
- AUST $1.38
- ALXO $0.45
- Resistance Level
- AUST $1.59
- ALXO $0.53
- Average True Range (ATR)
- AUST 0.10
- ALXO 0.05
- MACD
- AUST -0.04
- ALXO -0.01
- Stochastic Oscillator
- AUST 0.00
- ALXO 4.98
About AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.